Article Text

PDF
▼Teriparatide for postmenopausal osteoporosis
  • Relevant BNF section: 6.6.1

Abstract

▼Teriparatide (Forsteo - Eli Lilly) is the first parathyroid hormone derivative to be licensed for the treatment of women with postmenopausal osteoporosis. It is described as a "bone-formation agent",1 in contrast to established treatments, such as bisphosphonates, raloxifene, calcitriol and calcitonin, which reduce bone resorption.24 Here we consider whether teriparatide offers any worthwhile advantages over these other options.

Statistics from Altmetric.com

  • Relevant BNF section: 6.6.1

View Full Text

Footnotes

    Request permissions

    If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.